Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205152 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
A Phase 2 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 8
- Study locations
NCT01205152 is a Phase 2 study of Hypophosphatasia that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 10 participants, below the 82-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (88% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT01205152, a Phase 2 study of Hypophosphatasia, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 8
- Study locations
Study Summary
This clinical trial studied the long term safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP who completed study ENB-002-08 (NCT00744042). Partial funding for this study was provided by the Office of Orphan Product Development (OOPD).
Conditions Studied
Interventions
- BIOLOGICAL asfotase alfa
Study Locations (8)
Delaware
- Alfred I. DuPont Hospital for Children - Wilmington
Missouri
- St. John's Medical Research Institute - Springfield
Nebraska
- University of Nebraska Medical Center - Omaha
Tennessee
- Vanderbilt University Medical Center - Nashville
Wisconsin
- St. Vincent Hospital - Green Bay
Abu Dhabi Emirate
- Tawam Hospital - Al Ain City
Northern Ireland
- Royal Maternity Hospital, Royal Belfast Hospital for Sick Children - Belfast
Other
- Sheffield Children's Hospital - Sheffield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01205152
The ClinicalTrials.gov registry entry for NCT01205152 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (88% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypophosphatasia appearing as the primary indexed condition, and to 1 intervention - of which asfotase alfa is the first listed.
NCT01205152 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Delaware, Missouri, Nebraska.
Frequently Asked Questions
What is clinical trial NCT01205152 about?
NCT01205152 is a clinical study titled "Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)". This clinical trial studied the long term safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP who completed study ENB-002-08 (NCT00744042). Partial funding for this study was provided by the Office of Orphan Product Development (OOPD).
What is the current status of trial NCT01205152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2009-04. Estimated completion is 2016-08.
What conditions does trial NCT01205152 study?
This clinical trial studies the following conditions: Hypophosphatasia.
What interventions are being tested in trial NCT01205152?
The interventions under investigation include: asfotase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT01205152?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01205152 being conducted?
This trial has 8 study locations across Delaware, Missouri, Nebraska, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
United States Hypophosphatasia Molecular Research Center
RECRUITING
-
Natural History Study of Patients With Hypophosphatasia (HPP)
RECRUITING
-
A Prospective Sub-Study of the Global Hypophosphatasia Registry
RECRUITING
-
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.